Renascience Pharma is a UK based pharmaceutical company that aims to meet clinical need through the revival of forgotten critical medicines.
We have an experienced management team with proven success acquired across the global pharmaceutical industry and the NHS.
We are committed to launching a portfolio of medicines that will provide access and clinical options to physicians and patients.
The critical need for antibiotics has inspired Renascience to launch Renapime (Cefepime Dihydrochloride), the UK’s FIRST and ONLY approved 4th Generation Cephalosporin.
‘Revive Science, Restore Health’ is the ethos at Renascience enabling us to bridge the antibiotic discovery void.
Renascience values are fundamental to our mission - Revive Science, Restore Health.
These values are the compass of our business model, behaviour and decision making process.
Building on the foundations of patient focus, excellence, integrity and collaboration, we are proud to have cultivated a vibrant company culture where innovation can flourish, individuals can shine and success follows.
We focus on meeting the needs of individual patients.
We take pride in meeting patients' needs, regardless of rarity, diversity and gender.
We are committed to meeting these needs by delivering products of the highest quality to patient.
We achieve excellence by innovation.
We deliver excellence by doing the things that we say we will.
We are committed to achieve the best of Renascience in all situations.
We pledge to maintain the highest ethical and professional standards in all circumstances.
We uphold the values of honesty, sincerity and truthfulness.
We respect all individuals & organisations of their diverse background, experience, expertise, beliefs, approaches and preferences.
We collaborate always with trust and care.
We anticipate exceptional outcomes from the synergy of our contributions .
We believe collaboration enriches collaborators
Renapime 1g & 2g (Cefepime Dihydrochloride) Powder for injection/infusion
Product Licence Number:
10 x 1 vial pack
PL44696/001 & PL44696/002
Powder for solution for injection/infusion
11 George Street West
Company Reg: 09420886
VAT Reg: 229583674
General and Sales Enquiries
Medical Information Enquiries
OTIGO (phenazone/lidocaine hydrochloride) 40 mg/10 mg/g ear drops, solution
Otigo is licensed for local symptomatic treatment and relief of pain in the following diseases of the middle ear without tympanic perforation: acute, congestive otitis media; otitis in influenza and barotraumatic otitis.